Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,409 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Invasive Procedure Clear all

Conditions: Triple Negative Breast Cancer, Stage IV Breast Cancer, HER2 Negative, Invasive Breast Cancer
Interventions: Atezolizumab, Carboplatin, Laboratory Biomarker, Quality-of-Life Assessment; Drug · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Indianapolis, Indiana • Baltimore, Maryland + 3 more

Conditions: Chronic Respiratory Failure
Interventions: Nasal non-invasive ventilation with RAM cannula; Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 1 Day to 21 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neoplasms, Breast
Interventions: Trastuzumab, Paclitaxel, FEC75, Lapatinib; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Denver, Colorado + 18 more

Conditions: Respiratory Device Comfort
Interventions: Respiratory monitor patient interface.; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 20 Years to 49 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Transitional Cell Carcinoma of Bladder, Superficial Bladder Cancer
Interventions: Hyperthermia System, Mitomycin C; Device · Drug
Lead sponsor: Mark Dewhirst; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Breast Cancer
Interventions: nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery; Drug · Biological · Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Hays, Kansas • Kansas City, Kansas

Conditions: Performance Enhancement
Interventions: Transcranial direct current stimulation; Device
Lead sponsor: United States Army Aeromedical Research Laboratory; Federal
Eligibility: 18 Years to 40 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Fort Rucker, Alabama

Conditions: Pediatric Acute Respiratory Distress Syndrome (PARDS), Pediatric Respiratory Diseases, Lung Compliance
Interventions: Not listed
Lead sponsor: Northwell Health; Other
Eligibility: 0 Days to 18 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Cancer
Interventions: ziv-aflibercept; Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 2
States / cities: New York, New York • Nashville, Tennessee

Conditions: Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Cisplatin, Computed Tomography, Fluorouracil, Gemcitabine, Magnetic Resonance Imaging, Mitomycin, Pembrolizumab, Questionnaire Administration, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 145
States / cities: Tucson, Arizona • Fayetteville, Arkansas • Rogers, Arkansas + 103 more

Conditions: Placenta Accreta, Blood Pressure, Hemorrhage, Hemorrhage, Postpartum
Interventions: LiDCO CNAP Monitoring Equipment; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney Transplant Recipients
Interventions: Not listed
Lead sponsor: CareDx; Industry
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • Indianapolis, Indiana + 10 more

Conditions: Urinary Bladder Neoplasms
Interventions: AGEN1884, AGEN2034, Cisplatin, Gemcitabine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fungal Infection
Interventions: Posaconazole; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Transplant;Failure,Kidney, Transplant; Failure, Pancreas, Rejection Acute Renal, Rejection Acute Pancreas
Interventions: dd-cfDNA Blood Test; Diagnostic Test
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Madison, Wisconsin

Conditions: Minimally Invasive Surgical Procedure, Laparoscopic Gastric Banding, Laparoscopic Roux-en-Y Gastric Bypass, Laparoscopic Sleeve Gastrectomy, Laparoscopic Fundoplication Procedure, Laparoscopic Heller Myotomy, Laparoscopic Paraesophageal Hernia Repair, Laparoscopic Gastric Resection
Interventions: EndoLift Liver Retractor; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Atopic Dermatitis
Interventions: Biologic therapy versus no biologic therapy; Other
Lead sponsor: DermTech; Other
Eligibility: 1 Year and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: New York, New York • Rochester, New York

Conditions: Congestive Heart Failure, Ischemic Cardiomyopathy, Mitral Valve Prolapse, Mitral Regurgitation, Aortic Valve Disease, Tricuspid Regurgitation
Interventions: Not listed
Lead sponsor: Woolsthorpe Technologies, LLC; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 3
States / cities: Nashville, Tennessee • Houston, Texas

Conditions: Non-Muscle Invasive Bladder Carcinoma
Interventions: Accelerometry, BCG Solution, Electronic Health Record Review, Patient Discharge, Survey Administration; Procedure · Biological · Other + 1 more
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: OCD
Interventions: MagPro X100 by MagVenture; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Cerebral Vasospasm, Autonomic Nervous System Diseases
Interventions: Right-Sided Cervical Sympathetic Block at C6, Transcutaneous Auricular Vagal Nerve Stimulation (taVNS); Procedure · Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Gestational Diabetes, Pre-Eclampsia, Blood Pressure
Interventions: LabClasp; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetic Neuropathy, Painful
Interventions: Prolonged continuous theta burst stimulation (pcTBS); Procedure
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Search by objective public record fields.

Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

Implementation of Nasal Non-Invasive Ventilation With a RAM Cannula in the Inpatient /Outpatient Setting

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Comfort Evaluation of Non-Invasive Respiratory Monitor Interfaces

Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer

Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

Effects of Non-Invasive Brain Stimulation on Soldiers' Cognitive and Functional Performance

IPV and Lung Compliance in Invasively Ventilated Children

Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

CNAP vs IABP in Pregnant Women With Placenta Accreta

Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095

Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA

Evaluation of Safety and Efficacy of the EndoLift Liver Retractor

A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients

Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Rapid Non-Invasive Brain Stimulation for OCD (oTMS)

Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage

Glucose and Blood Pressure During Pregnancy

Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms